Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shire Human Genetic Therapies Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to a unique examiner and 1 distinct art unit, indicating a highly concentrated prosecution effort for its current filings. The presence of only one pending action suggests that the company is maintaining a very lean set of active applications at this time. GEORGE W KOSTURKO is the busiest examiner for this portfolio, currently overseeing the only pending office action.
Because there is only one distinct examiner involved, this individual is responsible for the company's current pending workload. Practitioners should prioritize understanding the specific preferences and past decisions of this single examiner, as they currently hold total influence over the company's active results in the Biotechnology & Pharmaceuticals sector. The fact that only 1 distinct art unit is involved simplifies the procedural landscape, as there is no need to manage different standards across multiple technical groups. This centralized prosecution model is focused entirely on the active matter, allowing for a specific strategy tailored to a single point of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSTURKO, GEORGE W | 1 | 54.6% | +49.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890578 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | KOSTURKO, GEORGE W | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890578 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | KOSTURKO, GEORGE W | 1621 | DP | Non-Final OA | — | Pending | Sep 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShire Human Genetic Therapies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
George W Kosturko has the most, with 1 of Shire Human Genetic Therapies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
